Research news last week featured US CRIPR genome-editing company Caribou Biosciences announcing positive early data on its ...

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved Pfizer’s extension to the licence of the ...

The last week or so has seen an escalation of the bidding war for US obesity-focused Metsera, with counter bids and law suits ...

Healthcare giant Johnson & Johnson has announced that the US Food and Drug Administration (FDA) has approved Caplyta ...

German pharma major Bayer announced new Phase III investigational data from the pivotal FINE-ONE trial showing that Kerendia ...

The US Food and Drug Administration (FDA) has approved Johnson & Johnson’s Darzalex Faspro (daratumumab and ...

Danish diabetes and obesity drug giant Novo Nordisk has agreed with the US Administration to lower drug prices beginning in ...

Biopharma company Pelthos Therapeutics has acquired the US commercialization rights to Xepi (ozenoxacin) Cream, 1%, from ...

Eli Lilly (NYSE: LLY) is preparing to start Phase III trials of its experimental obesity therapy eloralintide by year-end, ...

The Russian government has proposed a new mechanism for subsidization of works for development of new drugs, reports The ...

Danish pharma major Novo Nordisk (NOV: N) has presented new post-hoc analyses from the Phase III REDEFINE 1 trial evaluating ...

Danish biotech Genmab reported a 25% rise in its total revenue to $1.02 billion during the third quarter of 2025, ahead of ...